目的 探討長春胺緩釋膠囊聯(lián)合依達(dá)拉奉右莰醇注射用濃溶液治療急性腦梗死的臨床效果。方法 收集大慶油田總醫(yī)院2021年10月—2023年10月收治的105例急性腦梗死患者臨床資料，依據(jù)治療方案不同分為對照組（52例）和治療組（53例）。對照組依達(dá)拉奉右莰醇注射用濃溶液15 mL與0.9%氯化鈉注射液100 mL混合后靜脈滴注，2次/d。治療組在對照組基礎(chǔ)上口服長春胺緩釋膠囊30 mg/次，2次/d。兩組均持續(xù)用藥7 d。比較兩組臨床療效、神經(jīng)功能缺損情況、炎癥因子和氧化應(yīng)激指標(biāo)。結(jié)果 治療組總有效率高于對照組（P＜0.05）；治療后，兩組美國國立衛(wèi)生研究院卒中量表（NIHSS）評分均降低（P＜0.05），且治療組的NIHSS評分低于對照組（P＜0.05）。治療后，兩組血清白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）、丙二醛（MDA）水平均降低，血清超氧化歧化酶（SOD）水平升高（P＜0.05），且治療組炎癥因子和氧化應(yīng)激指標(biāo)變化優(yōu)于對照組（P＜0.05）。結(jié)論 在靜脈滴注依達(dá)拉奉右莰醇注射用濃溶液基礎(chǔ)上口服長春胺緩釋膠囊可顯著提高急性腦梗死患者臨床療效，有效改善神經(jīng)功能缺損情況，降低炎癥因子水平，減輕機(jī)體氧化應(yīng)激損傷。

Objective To explore the clinical efficacy of Vincamine Sustained Release Capsules combined with Edaravone and Dexborneol Concentrated Solution for injection in treatment of acute cerebral infarction. Methods Clinical data of 105 patients with acute cerebral infarction admitted to Daqing Oilfield General Hospital from October 2021 to October 2023 were collected, and were divide into control group (52 cases) and treatment group (53 cases) according to different treatment plans. In the control group, 15 mL Edaravone Dexborneol Concentrated Injection was mixed with 100 mL 0.9% sodium chloride injection and administered via intravenous infusion over 30 minutes, twice daily. Patients in the treatment group were po administered with Vincamine Sustained Release Capsules at a dose of 30 mg/time on the basis of the control group, twice daily. Both groups of patients continued to take medication for 7 d. The clinical efficacy, neurological deficits, inflammatory factors, and oxidative stress indicators were compared between two groups. Results The treatment group exhibited a superior overall response rate relative to the control group (P < 0.05). Post-treatment evaluation revealed statistically significant reductions in NIHSS scores across both groups (P < 0.05), and the treatment group demonstrating markedly lower NIHSS scores compared to the control group (P < 0.05). After treatment, the serum levels of IL-1β, TNF-α, and MDA were decreased in both groups, while the serum level of SOD was increased (P < 0.05). Treatment group inflammation and oxidative stress index change was better than those in the control group (P < 0.05). Conclusion On the basis of intravenous infusion of Edaravone and Dexborneol Concentrated Solution for injection, oral Vincamine Sustained Release Capsules can significantly improve the clinical effect of acute cerebral infarction, effectively improve the neurological deficit, reduce the level of inflammatory factors, and alleviate oxidative stress damage.

R971

收稿日期：2024-08-21